Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Day One Biopharmaceuticals, Inc. Market Cap
The Day One Biopharmaceuticals, Inc. (DAWN) share price is expected to increase by 176.41% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered DAWN. Price targets range from $24 at the low end to $54 at the high end. The current analyst consensus for DAWN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Day One Biopharmaceuticals, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Day One Biopharmaceuticals, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of DAWN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Anupam Rama JP Morgan | Overweight | $36 | Maintains | Aug 6, 2024 |
HC Wainwright& Co. | Buy | Reiterates | Aug 1, 2024 | |
| Alec Stranahan B of A Securities | Buy | $24 | Upgrade | Aug 1, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $40 | Reiterates | Aug 1, 2024 |
| Ami Fadia Needham | Buy | $32 | Maintains | Jul 31, 2024 |
| Ami Fadia Needham | Buy | $33 | Reiterates | Jul 30, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $40 | Reiterates | Jul 26, 2024 |
| Joseph Catanzaro Piper Sandler | Overweight | $40 | Maintains | Jul 8, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $40 | Reiterates | Jun 20, 2024 |
| Ami Fadia Needham | Buy | $33 | Reiterates | Jun 19, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $40 | Maintains | May 7, 2024 |
| Ami Fadia Needham | Buy | $33 | Reiterates | May 7, 2024 |
| Ami Fadia Needham | Buy | $33 | Reiterates | Apr 25, 2024 |
| Ami Fadia Needham | Buy | $33 | Maintains | Apr 24, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $50 | Reiterates | Apr 24, 2024 |
| Anupam Rama JP Morgan | Overweight | $36 | Maintains | Apr 22, 2024 |
| Joseph Catanzaro Piper Sandler | Overweight | $40 | Maintains | Mar 26, 2024 |
| Joseph Catanzaro Piper Sandler | Overweight | $40 | Maintains | Feb 28, 2024 |
| Matthew Biegler Oppenheimer | Perform | Reiterates | Feb 27, 2024 | |
| Andrea Tan Goldman Sachs | Buy | $44 | Maintains | Feb 27, 2024 |
When did it IPO
2021
Staff Count
169
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Jeremy Bender M.B.A., Ph.D.
Market Cap
$1.38B
In 2023, DAWN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that DAWN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Stock market volatility at new highs may indicate investor nervousness and potentially signal a market top, prompting caution among investors.
Why It Matters - Volatility at market highs may indicate potential downturns, prompting investors to reassess risk and adjust their portfolios to mitigate losses.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - OJEMDA TM (tovorafenib) generated $8.2 million in net product revenues within its first two months of launch, indicating strong initial market performance.
Why It Matters - Strong initial revenue from OJEMDA TM indicates robust market demand, potentially driving stock prices up and attracting investor interest in the company's growth prospects.
Tue, 30 Jul 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.61 per share a year ago.
Tue, 30 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Day One Biopharmaceuticals announced a private placement agreement, raising approximately $175 million in gross proceeds to support its targeted therapies for life-threatening diseases.
Why It Matters - Day One Biopharmaceuticals securing $175 million in an oversubscribed private placement indicates strong investor confidence, which could enhance its growth prospects and market position.
Thu, 25 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ipsen and Day One Biopharmaceuticals have formed a global partnership for tovorafenib, a treatment for pediatric low grade glioma, expanding its availability outside the U.S.
Why It Matters - The partnership enhances Ipsen's pipeline, potentially increasing revenue from a novel cancer treatment, while Day One gains global reach, impacting stock valuations and investor sentiment.
Tue, 18 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Day One has obtained an exclusive license for the development and commercialization of MTX-13 (DAY301), which received FDA IND clearance in April 2024.
Why It Matters - Day One's exclusive license for MTX-13, now FDA-approved for trials, positions the company for potential growth and market advantage in a promising therapeutic area, impacting its stock value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
